Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02656706 2026-04-13

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Phase 2 Active not recruiting

22 enrolled 10 charts

Dermatologic

Melanoma

NCT02834013 2026-04-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Phase 2 Active not recruiting

818 enrolled

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT02978625 2026-04-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Phase 2 Active not recruiting

68 enrolled

DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT03304639 2026-04-13

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Phase 2 Active not recruiting

9 enrolled 11 charts

Dermatologic

Carcinoma, Merkel Cell

NCT04708418 2026-04-13

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Phase 2 Active not recruiting

60 enrolled

Dermatologic

Melanoma

NCT05947500 2026-04-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Phase 2 Active not recruiting

50 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT04291885 2026-04-09

I-MAT

Phase 2 Active not recruiting

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT06101134 2026-04-09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase 2 Active not recruiting

100 enrolled 11 charts

Dermatologic

Melanoma, Neoplasm Metastasis, Patient Preference

NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Phase 2 Active not recruiting

26 enrolled 9 charts

Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT06099782 2026-04-08

MK-3475A-F11

Phase 2 Active not recruiting

147 enrolled 14 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06984328 2026-04-08

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

1 enrolled

Dermatologic

Melanoma, Recurrence

NCT04792073 2026-04-07

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Phase 2 Active not recruiting

18 enrolled

Dermatologic

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT05289193 2026-04-07

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Phase 2 Active not recruiting

28 enrolled

Dermatologic

Melanoma

NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Phase 2 Active not recruiting

7 enrolled

Dermatologic

Uveal Melanoma, Eye Neoplasms

NCT05130177 2026-03-31

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase 2 Active not recruiting

8 enrolled

Dermatologic

Melanoma

NCT04074096 2026-03-25

BEPCOME-MB

Phase 2 Active not recruiting

10 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT00338377 2026-03-20

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

1,230 enrolled

Dermatologic

Melanoma, Meningeal Neoplasms

NCT00937937 2026-03-20

Dinaciclib in Treating Patients With Stage IV Melanoma

Phase 2 Active not recruiting

72 enrolled 14 charts

Dermatologic

Melanoma

NCT04899908 2026-03-19

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Phase 2 Active not recruiting

134 enrolled

BreastCNSDermatologicGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms

NCT02068586 2026-03-16

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Phase 2 Active not recruiting

210 enrolled

Dermatologic

Uveal Melanoma

NCT05907954 2026-03-16

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Phase 2 Active not recruiting

160 enrolled

Dermatologic

Uveal Melanoma, Plaque, Amyloid

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting

134 enrolled

Dermatologic

Melanoma

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

Phase 2 Active not recruiting

50 enrolled 12 charts

Dermatologic

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

133 enrolled

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Active not recruiting

71 enrolled 9 charts

Dermatologic

Melanoma

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 2 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Phase 2 Active not recruiting

35 enrolled

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT01644591 2026-03-05

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

Phase 2 Active not recruiting

49 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

Phase 2 Active not recruiting

15 enrolled

DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Phase 2 Active not recruiting

14 enrolled 9 charts

Dermatologic

Melanoma

NCT03565783 2026-02-25

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Phase 2 Active not recruiting

44 enrolled

DermatologicHead & Neck

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT05912244 2026-02-17

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Phase 2 Active not recruiting

43 enrolled

Dermatologic

Melanoma

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Phase 2 Active not recruiting

58 enrolled

Dermatologic

Melanoma

NCT03767348 2026-02-13

IGNYTE

Phase 2 Active not recruiting

340 enrolled

DermatologicThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06190951 2026-02-10

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Phase 2 Active not recruiting

151 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06485219 2026-02-06

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Phase 2 Active not recruiting

50 enrolled

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03420508 2026-02-05

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Phase 2 Active not recruiting

18 enrolled

Dermatologic

Melanoma

NCT03944941 2026-02-05

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Phase 2 Active not recruiting

60 enrolled

Dermatologic

Skin Neoplasms

NCT05418972 2026-02-05

Neo ReNi II

Phase 2 Active not recruiting

20 enrolled

Dermatologic

Melanoma

NCT04645680 2026-01-30

DIET

Phase 2 Active not recruiting

50 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Phase 2 Active not recruiting

42 enrolled

Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT07376317 2026-01-29

OTIMAS

Phase 2 Active not recruiting

29 enrolled

Dermatologic

Melanoma

NCT06422936 2026-01-26

SPOTLIGHT204

Phase 2 Active not recruiting

60 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Phase 2 Active not recruiting

79 enrolled

DermatologicLymphoid

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell